The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Predicting the Risk of Recurrence Before the Start of Antithyroid Drug Therapy in Patients With Graves' Hyperthyroidism
Open accessAbstract
Treatment options of Graves' hyperthyroidism should be tailored to the needs of individual patients, taken into account recurrence risk, co-morbidities, and personal preferences. This study aimed to construct a prediction model to calculate recurrence risk after a course of antithyroid drugs, based on clinical and genetic parameters prior to the start of treatment. Consecutive, untreated patients with a first episode of Graves' hyperthyroidism were included in a prospective, multicenter, observational study. Before starting antithyroid drugs, clinical parameters and blood samples were collected. Antithyroid drugs were withdrawn after 1 year, and patients were followed for a further 2 years. Clinical and genetic markers that are independently associated with recurrent hyperthyroidism, and a multimarker prediction model for recurrence. Thirty-seven percent of 178 patients had recurrent Graves' hyperthyroidism within 2 years after antithyroid drug withdrawal. In Cox regression, lower age, higher serum free T4, higher serum thyrotropin-binding inhibitor immunoglobulin, larger goiter sizes at diagnosis, PTPN22 C/T polymorphism, and HLA subtypes DQB1*02, DQA1*05, and DRB1*03 were independent predictors for recurrence. Two simplified predictive models were constructed based on HRs of the multivariate model, called the Graves' Recurrent Events After Therapy (GREAT) score for clinical markers and the GREAT+ score for the combination of clinical and genetic markers. The GREAT and GREAT+ scores were divided into classes according to recurrence rates. Higher recurrence rates were observed in GREAT score class III (68%) compared with class II (44%) or class I (16%). The GREAT+ score showed much higher rates of recurrence in class IV+ (84%), compared with class III+ (49%), class II+ (21%), and class I+ (4%).The largest benefit of the GREAT+ score is in GREAT score class II: addition of genotypes changes recurrence risk (and thereby management) in 38%. Our prediction model based on simple clinical assessment, supplemented with genotyping at intermediate risk, can be of great value in individualized treatment of newly diagnosed patients with Graves' hyperthyroidism in routine clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
VITTI, P., RAGO, T., CHIOVATO, L., PALLINI, S., SANTINI, F., FIORE, E., ROCCHI, R., MARTINO, E., & PINCHERA, A. (1997) · Thyroid · doi:10.1089/thy.1997.7.369 · Cited by 293
Nedrebo, B., Holm, P., Uhlving, S., Sorheim, J., Skeie, S., Eide, G., Husebye, E., Lien, E., & Aanderud, S. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1470583 · Cited by 132
Cited by
2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism
Kahaly, G. J., Bartalena, L., Hegedüs, L., Leenhardt, L., Poppe, K., & Pearce, S. H. (2018) · European Thyroid Journal · doi:10.1159/000490384 · Cited by 940
Lee, S. Y., & Pearce, E. N. (2023) · JAMA · doi:10.1001/jama.2023.19052 · Cited by 295
Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis
Wiersinga, W. M., Poppe, K. G., & Effraimidis, G. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00005-0 · Cited by 254
Self-citation
Metadata
- Authors
- Vos, X. G., Endert, E., Zwinderman, A. H., Tijssen, J. G. P., & Wiersinga, W. M.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2016-04
- Volume
- 101
- Issue
- 4
- Pages
- 1381-1389
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2255614352
- Cited by
- 188
- References
- 2
- FWCI
- 13.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Predicting the Risk of Recurrence Before the Start of Antithyroid Drug Therapy in Patients With Graves' Hyperthyroidism. https://app.cochat.ai/papers/10.1210/jc.2015-3644
- The paper
- Vos, X. G., Endert, E., Zwinderman, A. H., Tijssen, J. G. P., & Wiersinga, W. M. (2016). Predicting the Risk of Recurrence Before the Start of Antithyroid Drug Therapy in Patients With Graves' Hyperthyroidism. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2015-3644
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.